1.Bohr, V, Hansen, BO, Kjersem, H et al. , Sequelae from bacterial meningitis and their relation to the clinical condition during acute illness, based on 667 questionnaire returns. J Infect 1983; 7: 102–10.
2.Greenwood, BM, Bradley, AK, Smith, AW, Wall, RA. Mortality from meningococcal disease during an epidemic in the Gambia, West Africa. Trans R Soc Trop Med Hyg 1987; 81: 536–8.
3.Halstensen, A, Pedersen, SHJ, Haneberg, B et al. , Case fatality of meningococcal disease in western Norway. Scand J Infect Bis 1987; 19: 35–42.
4.Cartwright, KAV, Stuart, M, Noah, ND. An outbreak of meningococcal disease in Gloucestershire. Lancet 1986; ii: 558–61.
5.Rønne, T, Lind, I, Buhl, LH, Poolman, JT, Zoffmann, H. Recurrent localized outbreaks of group C meningococcal disease and selective vaccination programmes. Anton Leeuwenhoek J Microbiol Serol 1986; 52: 221–2.
6.Ashton, FE, Ryan, A, Borczyk, AL, Caugant, DA, Mancino, L, Huang, D. Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. J Clin Microbiol 1991; 29: 2489–93.
7.Whalen, CM, Hockin, JC, Ryan, A, Ashton, F. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. Emergence of a virulent clone of Neisseria meningitidis. JAMA 1995; 273: 390–4.
8.Jackson, LA, Schuchat, A, Reevers, MW, Wenger, JD. Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA 1995; 273: 383–9.
9.Branham, SE. Serological relationship among meningococci. Bacterial Rev 1953; 17: 175–88.
10.Branham, SE. Reference strains for the serologie groups of meningococcus. Int Bull Bact Nomencl Taxon 1958; 8: 1–15.
11.Slaterus, KW. Serological typing of meningococci by means of micro-precipitation: Anton Leeuwenhoek J Microbiol Serol 1961; 27: 304–15.
12.Evans, JR, Artenstein, MS, Hunter, DH. Prevalence of meningococcal serogroups and description of three new groups. Am J Epidemiol 1968; 87: 643–6.
13.Ding, SQ, Ye, RB, Zhang, HC. Three new serogroups of Neisseria meningitidis. J Biol Stand 1981; 9: 307–15.
14.Ashton, FE, Ryan, A, Diena, B, Jennings, HJ. A new serogroup L of Neisseria meningitidis. J Clin Microbiol 1983; 17: 722–7.
15.Grahlow, WD, Kuzemenska, P. Meningitis in a child due to Neisseria meningitidis group K. Infection 1989; 17: 309–10.
16.Frasch, CE, Zollinger, WD, Poolman, JT. Serotype antigens of Neisseria meningitidis and proposed scheme for designation of serotypes. Rev Infect Dis 1985; 7: 504–10.
17.Abdillahi, H, Poolman, JT. Definition of meningococcal class I OMP subtype antigens by monoclonal antibodies. FEMS Microbiol Immunol 1988; 47: 139–44.
18.Ceesay, SJ, Allen, SJ, Menon, A et al. , Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization. J Infect Dis 1993; 167: 1212–6.
19.Käyhty, H, Karanko, V, Peltola, H, Sarna, S, Mäkela, PH. Serum antibodies to capsular polysaccharide vaccine of group A Neisseria meningitidis followed for three years in infants and children. J Infect Dis 1980; 142: 861–8.
20.Gold, R, Lepow, ML, Goldschneider, I, Gotschlich, EC. Immune response of human infants to polysaccharide vaccines of groups A and C Neisseria meningitidis. J Infect Dis 1977; 136: 831–5.
21.Lepow, ML, Goldschneider, I, Gold, R, Randolph, M, Gotschlich, EC. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics 1977; 60: 673–80.
22.Peltola, H, Mäkela, PH, Käyhty, H et al. , Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. New Engl J Med 1977; 297: 686–91.
23.Reingold, AL, Broome, CV, Hightower, AW et al. , Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985; ii: 114–18.
24.WHO Study Group. Cerebrospinal meningitis control. WHO Tech Rep 1976; Ser 588: 8–22.
25.Public Health Advisory Committee on Immunization Practices: Meningococcal polysaccharide vaccines. MMWR 1975; 24: 381–2.
26.Mäkela, PH, Käyhty, H, Weckstrom, P et al. , Effects of group A meningococcal vaccine in army recruits in Finland. Lancet 1975; ii: 883–6.
27.Stroffolini, T. Vaccination campaign against meningococcal disease in army recruits in Italy. Epidemiol Infect 1990; 105: 579–83.
28.Greenwood, BM, Wali, SS. Control of meningococcal infection in the African meningitis belt by selective vaccination. Lancet 1980; i: 729–32.
29.Greenwood, BM, Smith, AW, Hassan-King, M et al. , Theefficacyof meningococcal polysaccharide vaccine in preventing group A meningococcal disease in the Gambia, West Africa. Trans R Soc Trop Med Hyg 1986; 80: 106–7.
30.Mäkela, PH, Peltola, H, Käyhty, H et al. , Polysaccharide vaccines of group A Neisseria meningitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis 1977; 136 (suppl.): S43–S50.
31.Moore, PS, Toole, MJ, Nieburg, P, Waldman, RJ, Broome, CV. Surveillance and control of meningococcal meningitis epidemics in refugee populations. Bull WHO 1990; 68: 587–96.
32.Peltola, H. Group A meningococcal polysaccharide vaccine and course of the group A meningococcal epidemic in Finland. Scand J Infect Dis 1978; 10: 41–4.
33.Rønne, T, Berthelsen, L, Buhl, LH, Lind, I. Comparative studies on pharyngeal carriage of Neisseria meningitidis during a localized outbreak of serogroup C meningococcal disease. Scand J Infect Dis 1993; 25: 331–9.
34.Kuzemenska, P, Kriz, B. Epidemiology of meningococcal disease in Central and Eastern Europe. In Vedros, NA, ed. Evolution of meningococcal disease, vol I. Boca Raton, Florida: CRC Press, Inc, 1987: 103–37.
35.Kriz-Kuzemenska, P, Benes, C, Dlhy, J et al. , Increased incidence of invasive meningococcal disease in some regions in the Czech Republic caused by meningococcus C:2a:P1.2. Cs Epidemiol 1993; 42: 165–71.
36.Kriz, P, Musilek, M, Lebedova, V. New epidemiological situation in the Czech Republic caused by meningococcus C:2a:Pl.2(P1.5). Epidemiol Microbiol Immunol 1994; 43: 183–7.
37.Roznovsky, L, Matuska, J, Kriz-Kuzemenska, P. Unusual incidence of serious meningococcal diseases in some north Moravian districts in the first half of 1993. Prakt lek 1994; 74: 101–4.
38.Selander, RK, Caugant, DA, Ochman, H, Musser, JM, Gilmour, MN, Whitam, TS. Methods of multilocus enzyme electrophoresis for bacterial population genetics and systematics. Appl Environ Microbiol 1986; 51: 873–84.
39.Caugant, DA, Frøholm, LO, Bovre, K et al. , Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc Natl Acad Sci 1986; 83: 4927–31.
40.Kirkwood, BR. Essentials of medical statistics. Oxford: Blackwell Scientific Publications, 1988.
41. EGRET users manual. Seattle: Statistics and Epidemiology Research Corporation, 1988.
42.Cuevas, LE, Hart, CA. Chemoprophylaxis of bacterial meningitis. J Antimicrob Chemother 1993; 31 Suppl B: 79–91.
43.Lennon, D, Gellin, B, Hood, D, Voss, L, Heffernan, H, Thakur, S. Successful intervention in a group A meningococcal outbreak in Auckland, New Zealand. Pediatr Infect Dis J 1992; 11: 617–23.